Moreover, treatment with JNK inhibitor (SP600125) inhibited TNC-induced ADAM9 expression, and silencing ADAM9 in TNC-treated GBM cells suppressed cell migration and invasion. This evidence concerns the gene MAPK8 and glioblastoma.